NephroGenex Inc (NASDAQ:NRX) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Tuesday, Marketbeat.com reports. The brokerage currently has a $1.00 target price on the stock. Zacks Investment Research‘s price objective would suggest a potential upside of 14.88% from the stock’s current price.

According to Zacks, “NephroGenex, Inc. is a pharmaceutical company focused on the development of therapeutics to treat kidney disease. It is developing a small molecule drug that acts as an inhibitor of the pathogenic oxidative chemistries which are elevated in diabetic patients. NephroGenex, Inc. is based in United States. “

Separately, Rodman & Renshaw reaffirmed a “buy” rating on shares of NephroGenex in a research note on Sunday, January 24th.

Shares of NephroGenex (NASDAQ:NRX) traded down 5.7898% during trading on Tuesday, hitting $0.8201. 88,020 shares of the company traded hands. NephroGenex has a 52 week low of $0.77 and a 52 week high of $9.01. The company’s market capitalization is $10.62 million. The company has a 50 day moving average price of $1.36 and a 200 day moving average price of $2.83.

NephroGenex (NASDAQ:NRX) last posted its earnings results on Wednesday, November 11th. The company reported ($0.53) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.65) by $0.12. On average, analysts expect that NephroGenex will post ($2.32) earnings per share for the current year.

NephroGenex, Inc. is a pharmaceutical company. The Company is focused on the development of therapeutics to treat kidney disease. The Company is engaged in the development of Pyridorin (NASDAQ:NRX). Pyridorin targets the pathogenic oxidative chemistries that emerge in diabetic patients and lead to kidney disease. The Company’s product pipeline includes oral Pyridorin and intravenous (I.V.) Pyridorin. Oral Pyridorin is under development as a treatment for slowing the progression of diabetic nephropathy due to type 2 diabetes. I.V. formulation of Pyridorin is under development for the treatment of specific types of acute kidney injury (AKI). Pyridorin has received Fast Track Designation from the United States Food and Drug Administration (FDA), for the treatment of Diabetic Nephropathy.

12 Month Chart for NASDAQ:NRX

Get a free copy of the Zacks research report on NephroGenex (NRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for NephroGenex Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NephroGenex Inc and related companies with MarketBeat.com's FREE daily email newsletter.